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Abstract
Glial cell line-derived neurotrophic factor (GDNF) holds great promise for the treatment of Parkinson’s disease. In
humans, its intracerebroventricular administration leads to limiting side effects. Direct parenchymal delivery using
mechanical means, or cell and gene therapy represent potential alternatives. In the present study, a representative of each of
these three approaches, i.e. polymer rods, genetically modified encapsulated cells and lentiviral vectors was analyzed for its
ability to release GDNF in the striatum of rats. One week post-surgery, GDNF was detected over a distance of 4 mm with all
three methods. At 4 weeks GDNF staining diminished with rods and to a lesser extent with encapsulated cells, whereas it
increased with lentiviral vectors. Nanogram range of GDNF was measured with all methods at 1 week. At 4 weeks, GDNF
levels decreased significantly with rods, whereas they remained stable with encapsulated cells and lentiviral vectors. We
conclude that all three methods investigated allow striatal delivery of GDNF, but the time during which it needs to be
released will determine the approach chosen for clinical application.
  2002 Elsevier Science B.V. All rights reserved.
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1 . Introduction therapies with no effect on the onset or disease
progression. Efforts are thus being made to develop
Neurodegenerative disorders of the central nervous neuroprotection or even neuroregenerative strategies.
system (CNS) are characterized by a selective and Neurotrophic factors hold the greatest promise to
progressive degeneration of neuronal subpopulations achieve this goal.
leading to severe debilitating clinical symptoms. Neurotrophic factors (NTFs) are polypeptides
Current treatments consist mainly in symptomatic known to promote growth, survival and differentia-
tion of neurons during development, as well as
plasticity and structural integrity of the adult nervous
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diseases, such as nerve growth factor (NGF) for Buchs, Switzerland) was sieved to a size ,37 mm
Alzheimer’s disease (AD), glial cell line-derived using scrynel PET33HC meshes (PolyLabo). A 10%
neurotrophic factor (GDNF) for Parkinson’s disease (w/v) solution of purified EVA in methylene chloride
(PD), or ciliary neurotrophic factor (CNTF) for solvent was prepared with 23% BSA (w/w total) and
Huntington’s disease (HD) [1,2]. Several clinical 1% recombinant human GDNF (Amgen) (w/w
trials have been conducted with each of these factors, total), vortexed and sonicated until reaching a
so far, however, without success. Part of the prob- homogenous solution. The solution was then quickly
lems may be related to inefficient delivery technique. frozen and placed into a lyophilizer for 48–72 h until
The CNS delivery of NTFs is limited by factors the solvent was completely evaporated. The mixture
such as (i) their inability to cross the blood–brain- was pressure extruded at 55 8C through a cylindrical
barrier, (ii) their poor stability in a fluid environ- diameter die, and 10-cm-long rods were kept at 4 8C
ment, (iii) their limited diffusion through brain in a dessicator until use. Before implantation, 5-mm
parenchyma, and (iv) the side-effects associated with rods were cut and sterilized by immersion in 0.1 N
binding to extra-target receptors [3,4]. Intracereb- hydrochloric acid for 1 min, 70% ethanol for 1 min,
roventricular (ICV) administration eliminates the and sterile PBS for 2 min.
need to bypass the blood–brain-barrier. Poor diffu-
sion within the brain parenchyma [5,6] and occur- 2 .2. Characterization of the C C -GDNF cell line2 12
rence of severe side-effects limit, however, its ap-
plicability. Excruciating pain was indeed described The pCI-neo expression vector (Promega,
with the ICV administration of NGF in AD patients Madison, WI, USA) was modified as previously
[7,8]; weight loss, nausea and abnormal sexual described [11]. The fragment containing the mutated
behavior was reported with the ICV administration of dihydrofolate reductase gene (DHFR) under the
GDNF in PD patients [9]. In contrast, animal experi- control of the SV40 promoter and the hepatitis virus
ments have shown that direct parenchymal adminis- B 39 untranslated region (HBV-39 UTR) was ob-
tration dramatically reduces the occurrence of side- tained from the RP3224D plasmid [12] digested with
effects reported with ICV application [5,10]. These PvuII. The isolated fragment was subcloned into the
observations emphasize the need for localized, sus- pCI-Neo vector digested with BamHI and blunted,
tained delivery of these molecules in specific nuclei using the T4 polymerase to fill in the protruding
of the CNS. ends. The resulting vector pCI-ND was digested with
Direct localized CNS delivery is achievable either BglII and EcoRI to remove the cytomegalovirus
by mechanical means, or by cell or gene therapy. In (CMV) promoter. The murine phosphoglycerate
the context of this work, we have chosen to compare kinase 1 promoter and a chimeric intron excised
a representative of each of the three approaches for from the pCI-PGK-GIP-R/IRES/GLP-1 vector [13]
the intrastriatal delivery of GDNF, a promising via BglII /EcoRI digestion, was subcloned into the
trophic factor for the treatment of PD, and deduct the BglII /EcoRI site of the pCI-ND plasmid, forming
relative advantages /disadvantages of the three deliv- the pPI-DN vector. The plasmid pcDNA3 containing
ery techniques. the cDNA coding for the human GDNF with a
consensus Kozak sequence (a 636 bp fragment:
position 1–151 and 1–485 Genbank accession num-
2 . Materials and methods bers L19062 and L19063) was digested with
BamHI/HindIII and blunted. The GDNF fragment
2 .1. GDNF-releasing polymer rods was subcloned into the pPI-DN vector digested
EcoRI and blunted to create the pPI-DN-KZ-GDNF.
Ethylene-vinyl acetate copolymer (EVA; Elvax, Finally the Herpes Simplex Virus thymidine kinase
Dupont, Wilmington, USA) was cleaned by 20 (HSV-tk) gene obtained from the plasmid RP3224D
washes in absolute ethanol followed by 20 washes in digested with NotI was cloned into the BglII site of
sterile distilled water, and finally dried under a mild the pPI-DN-GDNF. The final plasmid named pPI-
vacuum. Bovine serum albumin (BSA; Sigma, DNT-KZ-GDNF was amplified in a standard E. coli
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strain (DH10B) and purified by a cesium chloride in the SIN-W-PGK transfer vectors. The viral par-
gradient. The integrity of the vector was verified by ticles were pseudotyped with the vesicular stomatitis
restriction analysis and sequencing. virus G protein, and produced by transient transfec-
C C mouse myoblasts (ATCC; CRL 1772, tion of 293T cells. High-titer stocks were obtained2 12
Rockville, MD, USA), transfected by calcium phos- by ultracentrifugation, and tested for the absence of
phate precipitation (Mammalian transfection kit, replication-competent viral vectors. The GDNF-ex-
Stratagene, La Jolla, CA, USA) with the pPI-DNT- pressing viral stocks were matched for viral particle
hGDNF plasmid, were selected with 0.8 mg/ml content (|110,000 ng p24 antigen/ml as measured
8G418 for 2 weeks, and the integrated plasmid was by ELISA assay) corresponding to |3–7310 TU/
then amplified with increasing concentrations of ml.
methotrexate (1 to 200 mM) over 4 weeks. Stability
of transgene expression was achieved by alternating 2 .5. Animals
cell incubation weekly in media containing either 0.8
mg/ml G418 or 200 mM methotrexate for an addi- Adult female Wistar rats (Iffa-Credo, France),
tional 6 weeks. The C C engineered cells were weighing 180–200 g were used in these studies.2 12
then maintained in culture media supplemented with They were housed in a controlled temperature room
0.8 mg/ml G418. Twenty-five clones isolated by that was maintained in a 12 h light /dark cycle. Food
limiting dilution were tested for GDNF secretion by and water were available ad libitum. The experi-
ELISA assay (R&D Systems, Abingdon, UK) as ments were carried out in accordance with the
well as for their differentiation and survival prop- European Community Council directive (86/609/
erties in hollow fibers. The clone [19 producing EEC) for care and use of laboratory animals.
6|0.26 mg hGDNF/10 cells /day was selected for
further studies. 2 .6. Surgical procedure
2 .3. Cell encapsulation Animals were anesthetized with an intraperitoneal
injection of sodium pentobarbital (50 mg/kg) and
C C cells were cultured in DMEM containing placed in a stereotaxic frame. Eighteen animals per2 12
10% fetal calf serum, 1% penicillin / streptomycin, group were then unilaterally implanted into the
and 2 mM L-glutamine (Life Technologies, Paisley, striatum with 5-mm-long GDNF-releasing polymer
Scotland, UK). After dissociation, cells were sus- rods (0.5 mm anterior to bregma, 3 mm lateral to the
pended at a density of 25,000 cells /ml culture midline, and 7 mm ventral from the dura), or with
medium. Six microliters (150,000 cells) of the cell 5-mm-long C C -GDNF capsules (0.5 mm anterior,2 12
solution were injected into 500-mm inner diameter 3 mm lateral, 7.5 mm ventral), or were injected with
poly(ether-sulfone) (PES) fibers (5 mm long; AKZO- 2 ml of concentrated lenti-GDNF (0.5 mm anterior, 3
Fiber Nobel, Wupperthal, Germany) previously filled mm lateral, 5 mm ventral) at the speed of |0.2
with a poly(vinyl) alcohol (PVA) cylindrical matrix ml /min.
(Rippey Corporation, CA, USA). The ends of the One week and 4 weeks post surgery, nine animals
fibers were sealed with a polymerized acrylic-based were sacrificed with an overdose of pentobarbital.
glue (Ablestic Laboratories, NJ, USA) and kept in Three were perfused transcardially with ice-cold
culture medium at 37 8C and 5% carbon dioxide phosphate buffer saline (PBS) containing 0.02%
before transplantation. ascorbic acid, their brains were removed and fresh
tissue punches (2.832 mm) in the striatum including
2 .4. GDNF-expressing lentiviral vectors the injection site were rapidly collected and kept at
280 8C before processing for hGDNF ELISA assay.
The generation of viral particles was performed The remaining six animals were perfused with PBS/
with a four-plasmid system as previously described ascorbic acid and with 4% paraformaldehyde. The
[14]. Briefly, the cDNAs encoding the human GDNF brains were post-fixed in a solution of 4% parafor-
containing a Kozak consensus sequence were cloned maldehyde for 24 h and then placed in 25% sucrose
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for an additional 24 h. They were then frozen on dry polymer rods or hollow fibers, and the injection of
ice and 25 mm coronal sections were cryocut lentiviral vectors into the rat striatum, immuno-
throughout the entire striatum and stored at 4 8C in histochemical detection of hGDNF was performed to
PBS containing 0.12 mM sodium azide. characterize the diffusion of the NTF throughout this
structure (Fig. 1). One week post-surgery, GDNF
2 .7. hGDNF ELISA assay staining was present over a maximal distance of 4
mm in the three groups, which almost corresponds to
Brain punches on the ipsi- and contralateral side the entire striatum volume according to the rat brain
(n53 per condition) were collected and processed to atlas of Paxinos and Watson [16] (Fig. 1A–C). Line
measure the amount of hGDNF using an ELISA source (polymer rods and encapsulated cells), as well
assay (Promega) as previously described [15]. as multiple point source (lentiviral vectors) delivery
techniques, show a similar pattern of GDNF staining.
2 .8. Immunohistochemical detection of hGDNF GDNF detection was restricted to the striatum as
delineated by the corpus callosum.
In order to evaluate the diffusion of GDNF in the Four weeks post-surgery, GDNF staining was
striatum, immunohistochemistry using biotinylated detected over |2 mm throughout the striatum in the
goat anti-human GDNF antibodies (R&D Systems, case of polymer rods (Fig. 1D), 3 mm with the
Abingdon, UK; 1:250) was performed on 25-mm-
thick cryosections as previously described [14].
2 .9. Image analysis
Diffusion of hGDNF was determined by digitizing
18 hGDNF-stained sections per animal (250 mm
between each section) throughout the entire striatum
with a slide scanner and quantifying the optical
density with an image analysis public domain pro-
gram (NIH-Image, Version 1.6.1, National Institutes
of Health, USA). Data are expressed as optical
density, corresponding to the sum of gray values of
all the pixels in the selection. The contralateral side
was used to determine the background density. The
corpus callosum and the anterior commissure were
used as hallmarks to delimit the striatal area.
2 .10. Statistical analysis
Data were analyzed for significance (set at P,
0.05) using analysis of variance (ANOVA) followed
by a Scheffe’s PLSD post-hoc test (JMP 3.0, SAS
Institute, USA).
3 . Results
Fig. 1. Serial reconstruction of photomicrographs showing
GDNF-immunostained striatal sections of rod- (A, D) and cap-3 .1. Diffusion pattern of GDNF in the striatum
sule-implanted (B, E), and lentiviral vector-injected (C, F)
animals. Immunohistochemical analysis was performed at either 1
One and 4 weeks following the implantation of week (A–C) or 4 weeks (D–F) post-surgery. Scale bar, 1 cm.
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encapsulated cells (Fig. 1E), and over 4 mm with volume. Interestingly, the ratio of the GDNF im-
lentiviral vectors (Fig. 1F). Only in the case of munostaining volume and the estimated striatal
lentiviral vectors was GDNF staining observed volume was not statistically different between the
beyond the striatum limits. rods, capsules and lentivirus (53.568.4%,
38.465.9%, and 45.663.9%, respectively) at the 1
3 .2. Optical density of GDNF staining week time point (Fig. 3). However, at 4 weeks
post-surgery, the three methods were statistically
In order to quantify and compare the diffusion different from the 1 week time point with a decrease
pattern of GDNF in the striatum using the three in this ratio for the rods (5.262.8%) and the
delivery methods, optical density of GDNF immuno- capsules (18.265.8%), and an increase for the
histochemical staining was measured throughout the lentivirus group (72.864.5%). Similar results were
entire striatum using the NIH image analysis pro- obtained in cubic millimeters and compared to the
gram (Fig. 2). One week post-surgery, optical den- estimated striatal volume (Table 1).
sity of GDNF staining obtained with rods (O.D.5
11.962.8), capsules (O.D.511.861.3) and lentiviral 3 .4. Amount of hGDNF detected in the striatum
vectors (O.D.59.661.0) were not statistically differ-
ent. At 4 weeks, however, both polymer rods and In order to compare the maximum levels of
encapsulated cells showed a significant decrease in hGDNF achieved by the different delivery methods,
optical density (O.D.51.060.4 and 4.760.6, respec- 2-mm-long striatal punches including the transplanta-
tively), whereas lentiviral vectors led to a significant tion / injection site were taken and processed for
increase in optical density (O.D.520.761.7) (Fig. ELISA assay. At 1 week post-surgery, |2 ng GDNF
2). per mg protein were detected with either rods,
capsules or lentiviral vectors (2.360.1, 260.1, and
3 .3. Volume of GDNF immunohistochemical 260.1 ng GDNF/mg protein, respectively) (Fig. 4).
staining in the striatum At 4 weeks post-surgery, the amount of GDNF
released by the polymer rods dramatically decreased
Using the same image analysis program, the (0.460.003 ng GDNF/mg protein), whereas cap-
volume of GDNF immunohistochemical staining was sules and lentiviral vectors showed sustained and
measured and compared to the ipsilateral striatal similar levels of GDNF around the injection site
Fig. 2. Quantification of the total amount of detected GDNF
based on the measurement of the optical density on GDNF- Fig. 3. Ratio of the volume of GDNF immunostaining and the
immunostained striatal sections at either 1 or 4 weeks post-surgery estimated striatal volume at either 1 or 4 weeks post-surgery from
from rod- and capsule-implanted as well as lentiviral vector- rod- and capsule-implanted as well as lentiviral vector-injected
injected animals. Values are expressed as mean6S.E.M. animals. Values are expressed as mean6S.E.M.
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Table 1
3Volume of GDNF immunohistochemical staining in the striatum and estimated striatal volume in mm at either 1 or 4 weeks post-surgery
from rod- and capsule-implanted as well as lentiviral vector-injected animals. Values are expressed as mean6S.E.M.
1 Week 4 Weeks
3 3Rods GDNF immuno volume 13.561.9 mm 1.360.7 mm
3 3Striatal volume 25.960.9 mm 24.360.6 mm
3 3Capsules GDNF immuno volume 10.361.6 mm 4.861.5 mm
3 3Striatal volume 27.161.4 mm 26.460.6 mm
3 3Lentivirus GDNF immuno volume 10.361.1 mm 19.661.5 mm
3 3Striatal volume 22.460.6 mm 26.961.2 mm
(1.760.3 and 1.760.05 ng GDNF/mg protein, re- localized expression of significant amounts of GDNF
spectively). At either 1 or 4 weeks post-surgery, in the striatum. Although the diffusion pattern of
contralateral values were similar to naive animals GDNF was approximately identical with the three
(,0.15 ng GDNF/mg protein), except for the len- approaches at 1 week post-surgery, results of the
tiviral vectors, where small amounts of GDNF were 4-week time point suggest that polymer rods are
detected at the 4-week time point (0.560.3 ng suitable for localized short-term protocols, whereas
GDNF/mg protein). The amounts of GDNF mea- lentiviral vectors and encapsulated cells are more
sured by ELISA assay represent maximum values in adapted methods for long-term applications.
localized punches around the injection site and not Several studies have reported encouraging results
absolute values within the entire striatum, thus using polymer rods releasing NTFs. Following a
explaining the discrepancies observed between Figs. fimbria–fornix lesion, NGF released from EVA/BSA
3 and 4 at the 4-week time point between capsules rods in the ipsilateral ventricle for 2 weeks prevented
and lentiviral vectors. the loss of choline acetyltransferase expression in the
medial septum and vertical diagonal band region
[17]. More recently, Tornqvist et al. have demon-
4 . Discussion strated that polymer rods secreting NTFs such as
epidermal growth factor, basic fibroblast growth
In the present study, we have compared the factor and GDNF can enhance fetal dopaminergic
efficiency of three different methods for delivery of graft survival, outgrowth, and functions, when co-
the neurotrophic factor GDNF in the brain paren- implanted with a striatal fetal graft in a rat model of
chyma of adult rats. Polymer rods, encapsulated cells PD [18]. Consistent with our results, they found that
and lentiviral vectors enable the continuous and polymer rods allowed the local secretion of the NTFs
for |2 weeks. Conceptually, polymer rods could be
applied in a clinical setting especially as they are
retrievable provided adequate geometry. Their use
will, however, be limited to applications necessita-
ting only short term delivery. As of today, EVA is
also not approved for clinical use.
Several studies have shown the ability of encapsu-
lated cells releasing NTFs to provide neuroprotection
and neuroregeneration both in rodent [19–23] and
primate [24,25] models of neurodegenerative dis-
orders. Scale-up in the human has already been
achieved through a phase I clinical trial using
Fig. 4. Amount of hGDNF in the ipsi- or contralateral striatum intrathecal implantation of 5-cm-long CNTF-releas-
measured by ELISA assay at either 1 or 4 weeks post-surgery
ing capsules in end-stage amyotrophic lateralfrom rod- and capsule-implanted as well as lentiviral vector-
injected animals. Values are expressed as mean6S.E.M. sclerosis patients [26,27]. The device was well
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tolerated and did not lead to significant side-effects. ly, a system allowing the regulation of transgene
Viable and functional encapsulated cells were still expression in the advent of limiting side-effects.
observed 17 weeks post-implantation. One of the Encouraging preliminary results have already been
most promising applications of NTFs consists in the obtained with lentiviral vectors encoding various
co-implantation of fetal mesencephalic cells with transgenes under the tetracycline-inducing system
encapsulated cells releasing GDNF [20]. GDNF [32,33].
indeed increases the number of surviving dopa-
minergic neurons as well as enhancing the neurite
outgrowth from these cells. Besides chronic delivery, 5 . Conclusion
the encapsulation technique also allows the treatment
to be arrested in case of appearance of limiting The present work reveals the efficiency of three
side-effects as capsules are retrievable by a simple different delivery methods in providing a significant
surgical procedure. amount of GDNF in the rat striatum. These data
The present study reveals the ability of lentiviral open interesting perspectives for the treatment of
vectors to lead to sustained delivery of GDNF in the neurodegenerative diseases. The dose and the time
rat striatum. GDNF staining was detected over a during which GDNF needs to be administered, i.e.
greater volume 4 weeks post-injection compared to 1 more detailed pharmacokinetics for the administra-
week. This observation is probably related to the tion of this trophic factor in the CNS will require
long half-life of GDNF within the brain parenchyma. further investigations to determine which one of
Previous experiments have reported long-term ex- these approaches would be particularly relevant in a
pression of the transgene up to 1 year in rodents [28] given clinical indication for the targeted neurode-
and 8 months in primates [15]. Long-term stable generative disease.
transgene expression is most probably related to the
integration of the viral genome into the host chromo-
some [29]. Surprisingly, some GDNF was also A cknowledgements
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